300233 金城医药
交易中 07-13 10:31:48
资讯
新帖
简况
金城医药（300233）股东淄博金城实业投资股份有限公司质押660万股，占总股本1.72%
证券之星 · 07-10 18:20
金城医药（300233）股东淄博金城实业投资股份有限公司质押660万股，占总股本1.72%
金城医药：通过精益管理、优化组织流程提升运营效能
证券之星 · 07-10 15:04
金城医药：通过精益管理、优化组织流程提升运营效能
金城医药（300233）披露控股股东部分股份质押及解除质押公告，7月9日股价下跌1.74%
证券之星 · 07-09
金城医药（300233）披露控股股东部分股份质押及解除质押公告，7月9日股价下跌1.74%
金城医药（300233）披露2026年半年度业绩预告，7月6日股价上涨0.68%
证券之星 · 07-06
金城医药（300233）披露2026年半年度业绩预告，7月6日股价上涨0.68%
金城医药最新公告：预计上半年净利润同比增长154%-223%
证券之星 · 07-06
金城医药最新公告：预计上半年净利润同比增长154%-223%
金城医药：预计上半年净利同比增154%-223%
格隆汇 · 07-06
金城医药：预计上半年净利同比增154%-223%
金城医药(300233)6月30日股东户数2.67万户，较上期减少0.79%
证券之星 · 07-06
金城医药(300233)6月30日股东户数2.67万户，较上期减少0.79%
金城医药：公司将不断提高信息披露质量
证券之星 · 07-02
金城医药：公司将不断提高信息披露质量
7月1日金城医药涨5.89%，大成景恒混合A基金重仓该股
证券之星 · 07-01
7月1日金城医药涨5.89%，大成景恒混合A基金重仓该股
6月29日金城医药涨6.91%，大成景恒混合A基金重仓该股
证券之星 · 06-29
6月29日金城医药涨6.91%，大成景恒混合A基金重仓该股
每周股票复盘：金城医药（300233）股东户数减少95户至2.69万户
证券之星 · 06-21
每周股票复盘：金城医药（300233）股东户数减少95户至2.69万户
金城医药(300233)6月10日股东户数2.69万户，较上期减少0.35%
证券之星 · 06-15
金城医药(300233)6月10日股东户数2.69万户，较上期减少0.35%
金城医药：公司基本面稳健，经营正常
证券之星 · 06-03
金城医药：公司基本面稳健，经营正常
金城医药(300233)5月29日股东户数2.7万户，较上期增加1.18%
证券之星 · 06-02
金城医药(300233)5月29日股东户数2.7万户，较上期增加1.18%
金城医药：截至2026年5月29日，公司股东总户数为27,004户
证券之星 · 06-02
金城医药：截至2026年5月29日，公司股东总户数为27,004户
金城医药(300233)5月20日股东户数2.67万户，较上期减少3.82%
证券之星 · 05-25
金城医药(300233)5月20日股东户数2.67万户，较上期减少3.82%
金城医药（300233）披露参股公司VGX-3100中国III期临床揭盲达主要终点，5月20日股价下跌0.93%
证券之星 · 05-20
金城医药（300233）披露参股公司VGX-3100中国III期临床揭盲达主要终点，5月20日股价下跌0.93%
金城医药（300233）披露子公司收到化学原料药上市申请批准通知书，5月14日股价下跌3.36%
证券之星 · 05-14
金城医药（300233）披露子公司收到化学原料药上市申请批准通知书，5月14日股价下跌3.36%
金城医药最新公告：子公司收到戊酸雌二醇原料药上市申请批准通知书
证券之星 · 05-13
金城医药最新公告：子公司收到戊酸雌二醇原料药上市申请批准通知书
雾麻科技(ISPR.US)通过与山东金城医药集团成立合资公司进军尼古丁口含袋(Nicotine Pouch)市场
智通财经 · 05-12
雾麻科技(ISPR.US)通过与山东金城医药集团成立合资公司进军尼古丁口含袋(Nicotine Pouch)市场
加载更多
公司概况
公司名称：
山东金城医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2011-06-22
主营业务：
山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、普罗雌烯乳膏、普罗雌烯氯喹那多阴道片以及注射用头孢唑林钠、注射用头孢他啶、注射用头孢呋辛钠、头孢羟氨苄胶囊、头孢克洛分散片、烟碱、4-AA、4-BMA、EDC、DIC。金城医化、金城汇海通过工信部“绿色工厂”复审，金城医化、金城生物、金城柯瑞通过重点行业绩效分级B级复审。
发行价格：
18.60
{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":13.18,"timestamp":1783909908000,"preClose":13.25,"halted":0,"volume":7907004,"delay":0,"changeRate":-0.0053,"floatShares":370000000,"shares":384000000,"eps":0.1744,"marketStatus":"交易中","change":-0.07,"latestTime":"07-13 10:31:48","open":13.2,"high":13.4,"low":13.05,"amount":105000000,"amplitude":0.0264,"askPrice":13.2,"askSize":283,"bidPrice":13.18,"bidSize":6,"shortable":0,"etf":0,"ttmEps":0.1744,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1783913400000},"marketStatusCode":2,"adr":0,"adjPreClose":13.25,"symbolType":"stock","openAndCloseTimeList":[[1783906200000,1783913400000],[1783918800000,1783926000000]],"highLimit":14.58,"lowLimit":11.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"isCdr":false,"pbRate":1.37,"roa":"--","peRate":75.573394,"roe":"1.57%","epsLYR":0.12,"committee":-0.008889,"marketValue":5059000000,"turnoverRate":0.0214,"status":1,"floatMarketCap":4874000000},"requestUrl":"/m/hq/s/300233","defaultTab":"news","newsList":[{"id":"2650181267","title":"金城医药（300233）股东淄博金城实业投资股份有限公司质押660万股，占总股本1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650181267","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650181267?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:20","pubTimestamp":1783678833,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药7月10日公开信息显示，股东淄博金城实业投资股份有限公司向国泰海通证券股份有限公司合计质押660.0万股，占总股本1.72%。质押详情见下表：截止本公告日，股东淄博金城实业投资股份有限公司已累计质押股份1740.0万股，占其持股总数的22.15%。金城医药主营业务：涵盖医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售等。本文数据来源于金城医药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000035885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907059","title":"金城医药：通过精益管理、优化组织流程提升运营效能","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650907059?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:04","pubTimestamp":1783667059,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药07月09日在投资者关系平台上答复投资者关心的问题。后续公司将持续聚焦主营业务、提升经营业绩；通过数字化升级、绩效改革等措施提升人均产出，持续强化关键人才梯队建设，加大核心人才引育留存力度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000021144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650940990","title":"金城医药（300233）披露控股股东部分股份质押及解除质押公告，7月9日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650940990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650940990?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:18","pubTimestamp":1783588682,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，金城医药报收于13.0元，较前一交易日下跌1.74%，最新总市值为49.9亿元。近日，金城医药披露《关于控股股东部分股份质押及解除质押的公告》。公告显示，山东金城医药集团股份有限公司于2026年7月8日接到控股股东淄博金城实业投资股份有限公司通知，金城实业将其持有的公司部分股份办理了质押及解除质押业务。本次变动后，金城实业累计质押股份占其所持股份比例为26.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900030268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649627223","title":"金城医药（300233）披露2026年半年度业绩预告，7月6日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649627223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649627223?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:36","pubTimestamp":1783348581,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘，金城医药报收于13.41元，较前一交易日上涨0.68%，最新总市值为51.48亿元。近日，山东金城医药集团股份有限公司发布2026年半年度业绩预告，预计2026年1月1日至6月30日归属于上市公司股东的净利润为11,000.00万元至14,000.00万元，同比增长153.55%至222.71%；扣除非经常性损益后的净利润为6,000万元至8,000万元，同比增长54.92%至106.56%。该数据未经注册会计师审计，最终数据以2026年半年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600037726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649623574","title":"金城医药最新公告：预计上半年净利润同比增长154%-223%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649623574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649623574?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:20","pubTimestamp":1783333209,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，预计2026年半年度归属于上市公司股东的净利润为1.10亿元-1.40亿元，同比增长153.55%-222.71%。业绩变动主要系中间体板块部分产品销量增加、产能利用率提高及非经常性损益增加所致。注：公司Q2净利润预计0.52亿-0.82亿，Q1净利润0.58亿，据此计算，Q2净利润预计环比变动-9%-42%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600028214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649623522","title":"金城医药：预计上半年净利同比增154%-223%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649623522","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649623522?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:15","pubTimestamp":1783332931,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640285","title":"金城医药(300233)6月30日股东户数2.67万户，较上期减少0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640285","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649640285?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:36","pubTimestamp":1783330595,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年6月30日公司股东户数为2.67万户，较6月10日减少213.0户，减幅为0.79%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年6月10日至2026年6月30日，金城医药区间涨幅为2.48%，在此期间股东户数减少213.0户，减幅为0.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600024621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648001025","title":"金城医药：公司将不断提高信息披露质量","url":"https://stock-news.laohu8.com/highlight/detail?id=2648001025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648001025?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:51","pubTimestamp":1782996711,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药07月01日在投资者关系平台上答复投资者关心的问题。不要用业绩回报这种空洞说辞搪塞金城医药回复：投资者，您好，感谢您的关注。公司高度重视市值管理工作，公司将不断提高信息披露质量，确保信息披露的真实、准确、完整；在投资者交流方面，公司通过投资者服务电话、业绩说明会、互动易平台等方式回应投资者诉求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200039637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516958","title":"7月1日金城医药涨5.89%，大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516958?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:51","pubTimestamp":1782895884,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日金城医药涨5.89%，收盘报13.13元，换手率3.4%，成交量12.59万手，成交额1.61亿元。重仓金城医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647516322","title":"6月29日金城医药涨6.91%，大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647516322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647516322?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:45","pubTimestamp":1782722720,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日金城医药涨6.91%创60日新低，收盘报12.84元，换手率3.65%，成交量13.51万手，成交额1.67亿元。重仓金城医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645962970","title":"每周股票复盘：金城医药（300233）股东户数减少95户至2.69万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2645962970","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645962970?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:25","pubTimestamp":1781983512,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，金城医药报收于12.66元，较上周的12.5元上涨1.28%。本周，金城医药6月18日盘中最高价报13.03元。6月16日盘中最低价报12.08元。金城医药当前最新总市值48.6亿元，在化学制药板块市值排名93/150，在两市A股市值排名3342/5206。股本股东变化股东户数变动截至2026年6月10日，公司股东户数为2.69万户，较5月29日减少95.0户，减幅为0.35%。户均持股数量由上期的1.42万股增加至1.43万股，户均持股市值为17.26万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643274198","title":"金城医药(300233)6月10日股东户数2.69万户，较上期减少0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643274198","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643274198?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:47","pubTimestamp":1781516829,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年6月10日公司股东户数为2.69万户，较5月29日减少95.0户，减幅为0.35%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至6月10日，化学制药行业平均股东户数为3.54万户。从股价来看，2026年5月29日至2026年6月10日，金城医药区间跌幅为7.91%，在此期间股东户数减少95.0户，减幅为0.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500022851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640226549","title":"金城医药：公司基本面稳健，经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2640226549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640226549?lang=zh_cn&edition=full","pubTime":"2026-06-03 08:46","pubTimestamp":1780447571,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价暴跌，公司经营是不是出问题了，现在生产设备开机率多少？金城医药回复：投资者，您好，二级市场股价受经济、行业环境、市场情绪等多种因素影响。公司基本面稳健，经营正常。公司将持续深耕主业、稳健经营，努力提升公司价值。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300009867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640591905","title":"金城医药(300233)5月29日股东户数2.7万户，较上期增加1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640591905","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640591905?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:36","pubTimestamp":1780392969,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年5月29日公司股东户数为2.7万户，较5月20日增加314.0户，增幅为1.18%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至5月29日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年5月20日至2026年5月29日，金城医药区间跌幅为11.93%，在此期间股东户数增加314.0户，增幅为1.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200033960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640993284","title":"金城医药：截至2026年5月29日，公司股东总户数为27,004户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640993284","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640993284?lang=zh_cn&edition=full","pubTime":"2026-06-02 08:45","pubTimestamp":1780361110,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好！截止5月29（31）号，股东人数多少？金城医药回复：投资者，您好，截至2026年5月29日，公司股东总户数为27,004户。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200008197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638318085","title":"金城医药(300233)5月20日股东户数2.67万户，较上期减少3.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638318085","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638318085?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:33","pubTimestamp":1779701591,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年5月20日公司股东户数为2.67万户，较5月10日减少1059.0户，减幅为3.82%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至5月20日，化学制药行业平均股东户数为3.57万户。从股价来看，2026年5月10日至2026年5月20日，金城医药区间跌幅为7.06%，在此期间股东户数减少1059.0户，减幅为3.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636882539","title":"金城医药（300233）披露参股公司VGX-3100中国III期临床揭盲达主要终点，5月20日股价下跌0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636882539","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636882539?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:31","pubTimestamp":1779287476,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，金城医药报收于14.92元，较前一交易日下跌0.93%，最新总市值为57.27亿元。金城医药于近日披露《关于参股公司研发项目的进展公告》。公告显示，公司参股公司东方略生物研发的VGX-3100在中国III期关键性注册临床研究中已揭盲，主要疗效结果达到预设的主要终点，安全性良好，未发现新的重大安全风险。VGX-3100为针对HPV-16/18相关宫颈高级别鳞状上皮内病变的治疗性DNA疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635718432","title":"金城医药（300233）披露子公司收到化学原料药上市申请批准通知书，5月14日股价下跌3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635718432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635718432?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:44","pubTimestamp":1778751865,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，金城医药报收于15.55元，较前一交易日下跌3.36%，最新总市值为59.69亿元。近日，山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，批准其化学原料药戊酸雌二醇上市申请。该原料药用于治疗与绝经相关的雌激素缺乏，目前全球范围内2023年至2025年三季度消耗量及销售额有所波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400032623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635009842","title":"金城医药最新公告：子公司收到戊酸雌二醇原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2635009842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635009842?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:49","pubTimestamp":1778665760,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司北京金城泰尔制药有限公司收到国家药监局下发的《化学原料药上市申请批准通知书》，批准戊酸雌二醇原料药注册。该药品主要用于补充与自然或人工绝经相关的雌激素缺乏。此次获批有利于丰富公司妇科产品线，提升市场竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211236","title":"雾麻科技(ISPR.US)通过与山东金城医药集团成立合资公司进军尼古丁口含袋(Nicotine Pouch)市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211236","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634211236?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:40","pubTimestamp":1778589639,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，雾麻科技今日宣布与全球性制药企业山东金城医药集团股份有限公司成立合资公司，共同生产并商业化尼古丁口含袋产品。根据协议条款，山东金城医药集团股份有限公司将向合资公司提供生产设备、工艺技术、生产品控体系以及高品质的尼古丁口含袋填充材料，从而使项目几乎能够立即投入运营，从而在短期内实现生产规模和收入的落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","300233","ISPR","BK4075"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783909912444,"stockEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":0.095},{"period":"3month","weight":-0.1325},{"period":"6month","weight":-0.101},{"period":"1year","weight":-0.204},{"period":"ytd","weight":-0.0438}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0302},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26696人(较上一季度减少0.79%)","perCapita":"13852股","listingDate":"2011-06-22","address":"山东省淄博市淄川区经济开发区双山路1号","registeredCapital":"38387万元","survey":" 山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、普罗雌烯乳膏、普罗雌烯氯喹那多阴道片以及注射用头孢唑林钠、注射用头孢他啶、注射用头孢呋辛钠、头孢羟氨苄胶囊、头孢克洛分散片、烟碱、4-AA、4-BMA、EDC、DIC。金城医化、金城汇海通过工信部“绿色工厂”复审，金城医化、金城生物、金城柯瑞通过重点行业绩效分级B级复审。","listedPrice":18.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}